CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective increased by equities research analysts at Needham & Company LLC from $85.00 to $88.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of […]
JMP Securities restated their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $74.00 price objective on the stock. Several other equities analysts have also commented on the company. Cantor Fitzgerald lowered CRISPR Therapeutics from an […]
ProShare Advisors LLC cut its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,254 shares of the company’s stock after selling 556 shares during the quarter. ProShare Advisors […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have issued a buy recommendation on […]